VSVenkateswaran Vellaichamy Swaminathan

Venkateswaran Vellaichamy Swaminathan

*This is an algorithmically generated author record based on publicly available information.

Venkateswaran Vellaichamy Swaminathan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Augmented immunosuppression and PTCY‐based haploidentical hematopoietic stem cell transplantation for thalassemia major

    by Venkateswaran Vellaichamy Swaminathan, Nikila Ravichandran, Kesavan Melarcode Ramanan, Satish Kumar Meena, Harika Varla, Balasubramaniam Ramakrishnan, Indra Jayakumar, Ramya Uppuluri, Revathi Raj

    Alternate donor HSCT for thalassemia major from a matched unrelated donor or haploidentical family donor is a feasible therapeutic option in children with no matched family donor. Aggressive pretransplant immunosuppression, reduced toxicity conditioning, and PTCY result in excellent thalassemia‐free survival. We describe here our experience in this cohort. We performed a retrospective analysis of the data on children who underwent a haploidentical HSCT for thalassemia major with PTCY at our center from August 2017 to August 2019. All children received pretransplant immune suppression for 6 weeks with fludarabine and dexamethasone, hypertransfusion and chelation with intravenous desferrioxamine. Conditioning included thiotepa, fludarabine, rabbit ATG, and cyclophosphamide, and GvHD prophylaxis included PTCY with tacrolimus. Twenty children were included and nineteen children engrafted. Acute hypertension occurred in five children, bacterial infection in eight children and viral respiratory infection in three children. Three children suffered from graft rejection. Reactivation of viruses namely CMV, adenovirus, and BK virus was seen in 60% of children. Grades 1‐2 acute GvHD of the skin in four children (20%) and limited chronic GvHD of the skin in four children (20%). Immune cytopenia was documented in three children (15%). Haploidentical HSCT offers a therapeutic option for children with thalassemia major with no suitably matched family or unrelated donors. Our reduced toxicity regimen with PTCY offers a DFS of 75% and OS of 95% with low transplant‐related mortality of 5%.


  • Safety and efficacy of fresh whole blood donor lymphocyte infusion in children

    by Venkateswaran Vellaichamy Swaminathan, Ramya Uppuluri, Shivani Patel, Meena Sivashankaran, Nikila Ravichandran, Kesavan Melarcode Ramanan, Balasubramaniam Ramakrishnan, Lakshman Vaidhyanathan, Revathi Raj

    Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism is seen with the use of reduced intensity conditioning. DLI can help prevent graft rejection by boosting the existing graft in these situations. There is scant data on the use of DLI in children who have undergone HSCT for benign hematological disorders. We present our case series with early withdrawal of immunosuppression and DLI as a means to mitigate relapse of leukemia and prevent graft rejection in mixed chimerism in children transplanted for benign hematological disorders. Donor lymphocyte infusion was given in a graded regimen with the cell dose of 1 × 105 CD3 cells/kg (1 × 104/kg in haploidentical transplant), 5 × 105 CD3 cells/kg, 1 × 106 CD3 cells/kg depending on the graft kinetics and the clinical status of the children. A total of fifty eight children including those with haploidentical donors underwent DLI with an overall survival of 81.1%. The use of fresh whole blood in very small aliquots from the donor has made this technique cost effective and an attractive form of immunotherapy.


  • Open Access

    Haploidentical Stem Cell Transplantation in Children with Benign Disorders: Improved Survival and Cost-Effective Care Over 15 Years from a Single Center in India

    by Ramya Uppuluri, Meena Sivasankaran, Shivani Patel, Venkateswaran Vellaichamy Swaminathan, Nikila Ravichandran, Kesavan Melarcode Ramanan, Lakshman Vaidhyanathan, Balasubramaniam Ramakrishnan, Indira Jayakumar, Revathi Raj

    We present our experience in haploidentical stem cell transplantation (haplo SCT) in children with benign disorders. We performed a retrospective study where children aged up to 18 years diagnosed to have benign disorders and underwent haplo SCT from 2002 to September 2017 were included. Of the 54 children, the most common indications were Fanconi anaemia 12 (22%), severe aplastic anaemia 8 (14%) and primary immune deficiency disorders (PID) 25 (46%). Post-transplant cyclophosphamide (PTCy) was used in 41 (75.9%) and ex vivo T depletion in 13 (24.1%). Engraftment rates were 70% with acute graft versus host disease in 36% and cytomegalovirus reactivation in 55% children. There was a statistically significant difference found between survival with siblings as donors as compared to parents (p value 0.018). Overall survival was 60% which is the 1-year survival, with 68% survival among those with PIDs. Cytokine release syndrome was noted in 12/41 (29%) of children who received T replete graft and PTCy. In children over 6 months of age, PTCy at a cost of INR 1200 provides cost effective T cell depletion comparable with TCR α/β depletion priced at INR 1200,000. Haplo SCT is feasible option for cure in children with benign disorder.


  • Quality Matters–Hematopoietic Stem Cell Transplantation versus Transfusion and Chelation in Thalassemia Major

    by Shivani Patel, Venkateswaran Vellaichamy Swaminathan, V Sr. Mythili, M Sr. Venkatadesikalu, Meena Sivasankaran, Dhaarani Jayaraman, R Balasubramaniam, Ramya Uppuluri, Revathi Raj

    Objective To compare quality of life of children with thalassemia major who have undergone stem cell transplantation with those on regular transfusion. Methods The study included 40 children who underwent transplantation and 40 children and 20 adults on regular transfusion and iron chelation therapy. The quality of life assessment was done using the Pediatric Quality of Life Inventory 4.0 Generic Core Scale. Results The mean total summary score, psychosocial summary score and physical score was 92, 91 and 92.8, respectively in transplant group and 83, 82.7 and 83.6, respectively in children in transfusion group. The adult group on transfusion showed overall poorer scores of 74.9, 76 and 73.9, respectively. The average scores in all domains were significantly (P<0.05) lower and drop steeply in second decade in transfusion group. Conclusion Allogeneic stem cell transplantation improves quality of life in thalassemia major.